Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

e now fully enrolled, and we expect initial data from this program to be reported in late 2010. A Phase 2 study (called DA VINCI) of VEGF Trap-Eye for the treatment of the Diabetic Macular Edema (DME) is also fully enrolled, with data expected during the first half of 2010. Additionally, two Phase 3 studies in Central Retinal Vein Occlusion (CRVO) are enrolling patients; data from the first of these studies are anticipated to be available in the first half of 2011.

During October 2009, 24-month results of the extension stage of the Phase 2 study of VEGF Trap-Eye in wet AMD (CLEAR-IT 2) were presented at the 2009 American Academy of Ophthalmology meeting. After receiving VEGF Trap-Eye for one year, the 117 patients who elected to enter the extension stage were dosed on a 2.0 mg PRN basis, irrespective of the dose at which they were treated earlier in the study. On a combined basis, for these 117 patients, the mean gain in visual acuity was 7.3 letters (p<0.0001 versus baseline) at the three-month primary endpoint of the original Phase 2 study, 8.4 letters (p<0.0001 versus baseline) at one year, and 6.1 letters (p<0.0001 versus baseline) at month 12 of the extension study. Thus, after 24 months of dosing with VEGF Trap-Eye in the Phase 2 study, patients continued to maintain a highly significant improvement in visual acuity versus baseline, while receiving, on average, only 4.6 injections over the 21-month PRN dosing phase that extended from month three to month 24. The most common adverse events were those typically associated with intravitreal injection.

Bayer HealthCare has rights to market VEGF Trap-Eye outside the United States, where the companies will share equally in profits from any future sales of VEGF Trap-Eye. Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States.

Monoclonal Antibodies

During the third quarter of 2009, REGN475, an antibody to Ner
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
...  -- Ametros Financial Corporation and Ringler Medicare Solutions, ... a partnership to offer Professional Administration services to ... and Life Care Planning services currently offered by ... http://photos.prnewswire.com/prnh/20120406/CG83519 ) Insurers, third-party administrators and ...
... Inc. , a clinical-stage epigenetics oncology company, announced Arthur ... "We are delighted to have Art Pappas ... a former senior level pharmaceutical executive and as a highly ... chairman of the Syndax board of directors.  "As Syndax ...
Cached Medicine Technology:Ametros Financial and Ringler Medicare Solutions Announce Partnership to Provide Professional Administration Services 2Syndax Pharmaceuticals Appoints Arthur M. Pappas to Board of Directors 2
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
(Date:4/23/2014)... Washington, April 21, 2014 Five for-profit and ... of $1.25 million in Proof of Concept grants ... ideas into commercial products, the Life Sciences Discovery ... $300,000 Entrepreneur Mentoring Program grant to the Washington ... statewide advisory network to train the next generation ...
(Date:4/23/2014)... Time Physical Activity on Mobility Limitation in Old Age ... risk of mobility limitation in old age, whereas leisure-time ... a study which followed up 5,200 public sector employees ... Gerontology Research Center in Finland and the Finnish Institute ... repetitive, wears the body and lasts for several hours ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... Improved Health Care Access and ... ... health care experience for patients and,practitioners alike, AT&T (NYSE: T ... deliver the country,s first statewide health,information exchange., The Tennessee Information ...
... Acuo Technologies is a market,leading provider of comprehensive ... collaboration and migration services. Recently,there has been an ... the,increasing size of digital imaging archives caused by ... onset of new contributors,like digital pathology systems. Many ...
... DELHI, Feb. 25, 2008 A vaginal microbicide that incorporates ... HIV is safe for sexually active HIV-negative women to use ... clinical trial of tenofovir topical gel. Moreover, most of the ... the United States adhered to a regimen involving either daily ...
... 25 Every Step Counts Organization in,association with ... Forest Park will continue its efforts to celebrate ... will host "Walk In,Her Shoes" 2008, a unique ... --,St. Louis and Atlanta. Designer shoes featured in ...
... Can Leverage WLAN Infrastructure to Improve Patient Care with Visibility ... ... Personnel, WALTHAM, Mass., Feb. 25 Colubris ... and,service providers, today announced that the company is working with,AeroScout, Inc., ...
... Wireless ECG Devices Help Healthcare Organizations Deliver Clinical ... Data Faster ... Colubris Networks, the leading,global provider of intelligent wireless LANs ... Science Corporation,(Nasdaq: CSCX ) ( http://www.cardiacscience.com ), the ...
Cached Medicine News:Health News:AT&T to Deliver Country's First Statewide eHealth Exchange Zone 2Health News:AT&T to Deliver Country's First Statewide eHealth Exchange Zone 3Health News:AT&T to Deliver Country's First Statewide eHealth Exchange Zone 4Health News:AT&T to Deliver Country's First Statewide eHealth Exchange Zone 5Health News:Acuo Technologies(R) Offers Free Migration Archive License 2Health News:Acuo Technologies(R) Offers Free Migration Archive License 3Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 2Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 3Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 4Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 5Health News:Trial finds tenofovir gel safe for daily use and most women adhered to study regimens 6Health News:Shoe Therapy Helps Survivors Celebrate Life After Abuse 2Health News:Colubris Partners with AeroScout to Enable Real-time Location Detection over Wireless Networks 2Health News:Colubris Partners with AeroScout to Enable Real-time Location Detection over Wireless Networks 3Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 3
Inquire...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: